Invivyd, Inc. (IVVD)

Market Cap	508.67M +227.1%
Revenue (ttm)	53.43M +110.5%
Net Income	-52.49M
EPS	-0.30
Shares Out	282.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,877,911
Open	1.880
Previous Close	1.900
Day's Range	1.780 - 1.900
52-Week Range	0.460 - 3.070
Beta	0.61
Analysts	Strong Buy
Price Target	8.75 (+386.11%)
Earnings Date	Mar 5, 2026

About IVVD

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and trea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Financial Performance

In 2025, Invivyd's revenue was $53.43 million, an increase of 110.47% compared to the previous year's $25.38 million. Losses were -$52.49 million, -69.11% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price target is $8.75, which is an increase of 386.11% from the latest price.

Price Target

$8.75

(386.11% upside)

Analyst Consensus: Strong Buy